Dowlati and coworkers have analyzed the possible correspondence between molecular abnormalities and response ton therapy in 39 SCLC patients and observed that patients with mutant RB1 (observed in 58% of patients) had better overall survival and progression-free survival compared with patients with wild-type RB1 [102]. The gene discussed is RB1; the disease is small cell lung carcinoma.